Gilead Sciences Inc (GILD – Analyst Report) is an American biopharmaceutical company that is well-known for developing and commercializing antiviral drugs that help to treat patients infected with HIV, Hepatitis B, and Hepatitis C. The company has over 19 drugs in its core pipeline.

Currently, Gilead Sciences has a Zacks Rank #3 (Hold) but is subject to change following the release of the company’s latest earnings report. We have highlighted some of the key statistics from this just announced report below.

Gilead Sciences:

1. Beat earnings estimates. The company posted $3.19 EPS, surpassing our Zacks Consensus Estimate of $3.03 (this number excludes $0.13 from non-recurring items).

2. Beat revenue estimates. The company saw revenue figures of $8.3 billion, beating our estimate of $8.075 billion.

3. Posted non-GAAP net income of $4.8 billion, a year-over-year increase from $3 billion in third quarter 2014.

4. Saw an increase in total product sales from third quarter 2014. The company posted sales of $8.2 billion, up from $6 a year ago.

5. GILD was up $2.48, or 2.28%, to $111.05 as of 4:18 PM ET in after hours trading shortly after its earnings report was released.

Here’s a look at Gilead Science’s recent quarterly EPS and growth rate:
 

Gilead Sciences Inc. (GILD – Analyst Report) Recent Quarterly EPS & Growth Rate | FindTheCompany